Synthorx Inc Expected to Earn Q1 2019 Earnings of ($0.33) Per Share (THOR)
Synthorx Inc (NASDAQ:THOR) – Stock analysts at Jefferies Financial Group issued their Q1 2019 earnings estimates for shares of Synthorx in a research report issued to clients and investors on Wednesday, March 13th. Jefferies Financial Group analyst B. Amin expects that the medical instruments supplier will post earnings per share of ($0.33) for the quarter. Jefferies Financial Group has a “Buy” rating and a $21.00 price target on the stock. Jefferies Financial Group also issued estimates for Synthorx’s Q2 2019 earnings at ($0.39) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($1.52) EPS, FY2020 earnings at ($2.94) EPS, FY2021 earnings at ($2.99) EPS, FY2022 earnings at ($2.98) EPS and FY2023 earnings at ($3.53) EPS.
Synthorx (NASDAQ:THOR) last posted its earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.77).
Synthorx stock opened at $19.21 on Friday. Synthorx has a fifty-two week low of $11.00 and a fifty-two week high of $23.53. The company has a market capitalization of $617.45 million and a P/E ratio of -2.92.
Several large investors have recently bought and sold shares of THOR. RA Capital Management LLC acquired a new position in shares of Synthorx in the fourth quarter worth $169,014,000. Orbimed Advisors LLC acquired a new position in shares of Synthorx in the fourth quarter worth $92,398,000. FMR LLC acquired a new position in shares of Synthorx in the fourth quarter worth $38,559,000. Matisse Capital acquired a new position in shares of Synthorx in the fourth quarter worth $956,000. Finally, Dean Capital Investments Management LLC acquired a new position in shares of Synthorx in the fourth quarter worth $827,000. Institutional investors and hedge funds own 75.85% of the company’s stock.
Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.
Featured Article: What is a Futures Contract?
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.